Companies › Bicara Therapeutics
1 active drug program in 5 registered trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ficerafusp alfa (BCA101) Bispecific antibody targeting EGFR and TGF-β | EGFR, TGFB1 | Phase 2 | Metastatic Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of Head and Neck (SCCHN) | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04429542 | Ficerafusp alfa (BCA101) | Phase 1 | Head and Neck Squamous Cell Carcinoma | Oncology | Oct 2027 |
| NCT07807163 | Ficerafusp alfa (BCA101) | Phase 2 | Metastatic Head and Neck Squamous Cell Carcinoma | Oncology | Mar 2028 |
| NCT06788990 | Ficerafusp alfa (BCA101) | Phase 2 | Metastatic Head and Neck Squamous Cell Carcinoma | Oncology | Apr 2028 |
| NCT07465276 | Ficerafusp alfa (BCA101) | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Oncology | Apr 2028 |
| NCT07529873 | Ficerafusp alfa (BCA101) | Phase 2 | Squamous Cell Carcinoma of Head and Neck (SCCHN) | Oncology | Apr 2030 |
Cash and short-term investments of $442m on 2026-09-30; operating cash outflow about $185m a year; runway about 29 months at that burn, to Feb 2029; 3 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.